# Impact of Symptomatic Versus Asymptomatic Breast Cancer Recurrence on Survival: A Retrospective Study of 238 Patients

**Authors:** Jun Yamamura, Shione Inoue, Maika Yoshioka, Shunji Kamigaki

PMC · DOI: 10.7759/cureus.102443 · Cureus · 2026-01-27

## TL;DR

This study found that breast cancer patients who experience asymptomatic recurrence tend to have better survival rates than those with symptomatic recurrence.

## Contribution

The study identifies a significant association between symptom status at recurrence and post-recurrence survival in breast cancer patients.

## Key findings

- Asymptomatic breast cancer recurrence was linked to longer survival (3.58 years) compared to symptomatic recurrence (2.06 years).
- Asymptomatic patients had earlier detection of recurrence via imaging compared to blood tests.
- Older age and certain tumor subtypes worsened outcomes in symptomatic recurrence cases.

## Abstract

Background

The relationship between symptoms at breast cancer recurrence and post-recurrence survival remains poorly understood. This study aimed to evaluate factors influencing survival after recurrence based on the presence or absence of symptoms at the time of breast cancer recurrence.

Methods

We retrospectively reviewed the records of 238 patients diagnosed with the first distant recurrent breast cancer between January 2000 and December 2019. Post-recurrence survival was analyzed based on whether the first distant recurrence was symptomatic or asymptomatic and stratified by clinical and pathologic characteristics. Significant prognostic factors related to post-recurrence survival were identified.

Results

For the entire cohort, the median overall survival after recurrence was 2.06 years for symptomatic patients at recurrence and 3.58 years for asymptomatic patients at recurrence (p = 0.006). Among symptomatic patients at recurrence, those aged > 50 years, with positive lymph nodes, or with hormone receptor-positive/HER2-positive subtype exhibited significantly worse prognoses than those without symptoms at recurrence. In asymptomatic patients at recurrence, the first distant recurrence was detected significantly earlier using imaging modalities than using blood tests.

Conclusion

Symptom status at first distant breast cancer recurrence may be associated with post-recurrence survival, with asymptomatic recurrence showing more favorable outcomes.

## Linked entities

- **Diseases:** breast cancer (MONDO:0004989)

## Full-text entities

- **Genes:** ESR1 (estrogen receptor 1) [NCBI Gene 2099] {aka ER, ESR, ESRA, ESTRR, Era, NR3A1}, MUC1 (mucin 1, cell surface associated) [NCBI Gene 4582] {aka ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, NR4A1 (nuclear receptor subfamily 4 group A member 1) [NCBI Gene 3164] {aka GFRP1, HMR, N10, NAK-1, NGFIB, NP10}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, CEACAM3 (CEA cell adhesion molecule 3) [NCBI Gene 1084] {aka CD66D, CEA, CGM1, CGM1a, W264, W282}, TENM1 (teneurin transmembrane protein 1) [NCBI Gene 10178] {aka ODZ1, ODZ3, TEN-M1, TEN1, TNM, TNM1}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}
- **Diseases:** stage IV metastatic disease (MESH:D007676), nodal (MESH:D013611), metastasis (MESH:D009362), death (MESH:D003643), triple negative breast cancer (MESH:D064726), Breast Cancer (MESH:D001943), node metastases (MESH:D008207), Cancer (MESH:D009369)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12946204/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12946204/full.md

## References

28 references — full list in the complete paper: https://tomesphere.com/paper/PMC12946204/full.md

---
Source: https://tomesphere.com/paper/PMC12946204